Main Article Content

Abstract

Background: The NLRP3 inflammasome is a crucial constituent of innate immunity, mediating caspase-1 stimulation and the production of pro-inflammatory cytokines Interleukin one and Interleukin-18. Still, abnormal activating of the NLRP3 inflammasome is being connected to a number of inflammatory diseases, such as diabetes, and atherosclerotic cardiovascular disease. Cardiovascular diseases are still widespread with significant deaths and morbidity ratios. Most CVDs are caused by vascular damage, including atherosclerosis, aneurysms, and subsequent ischemic heart conditions.   Aim of the study: Evaluation of NLRP3 inflammasome activity in cardiovascular diseases.Methodology: This study (cross-sectional study) included 200 individuals with cardiovascular disorders from January 2022 and May . The patients ranged in age from (1 to 80) years old, with 58 females and 142 males among the 200 cases. The serum samples of patients were obtained for screening of the presence of   NLRP3 Inflammasome by ELISA using commercial kits (SUNLONG_CHINA).Results: Patients with cardiovascular disease were divided into 4 aging groups as, the following: The 1st  age group (<20) yrs. old, The 2nd age group (20-39) yrs. old, The 3rd age group (40-59) yrs. old, and the last group,  is(60-79). The results clearly showed that a high percentage of ischemic heart disease was present among all age groups compared to others types followed by structural heart disease. The current study's cardiovascular patients were higher in males compared to females by about 142(71%) vs 58(29%) of all 200 participants. The study indicates that significant results for NLRP3  inflammasome were present among age groups patients with a p-Value equal to 0.03, it also indicates that there are no significant results for NLRP3  inflammasome among sex groups of patients with a p-Value equal to 0.402. And also an association between CVD and study marker showed no significant difference between seropositive NLRP3  inflammasome with cardiovascular disease types.


Conclusions: The most common cardiovascular type in the study was ischemic heart disease. Cardiovascular disease affects men more than women, and it gets worse as people get older.

Keywords

NLRP3 Inflammasome, Cardiovascular Diseases, CVD, Najaf Governorate

Article Details

How to Cite
Adnan Kadhem, D. ., & Jabbar Yasir, S. (2022). Evaluation Of NLRP3 Inflammasome Activity In Cardiovascular Diseases Patients In Najaf Governorate . Medical Science Journal for Advance Research, 3(4), 184–191. https://doi.org/10.46966/msjar.v3i4.83

References

  1. • Anand, S. S., Hawkes, C., De Souza, R. J., Mente, A., Dehghan, M., Nugent, R., Zulyniak, M. A., Weis, T., Bernstein, A. M., Krauss, R. M., Kromhout, D., Jenkins, D. J. A., Malik, V., Martinez-Gonzalez, M. A., Mozaffarian, D., Yusuf, S., Willett, W. C., & Popkin, B. M. (2015). Food Consumption and its Impact on Cardiovascular Disease: Importance of Solutions Focused on the Globalized Food System A Report from the Workshop Convened by the World Heart Federation. Journal of the American College of Cardiology, 66(14), 1590–1614.
  2. • Andersson, C., & Vasan, R. S. (2018). Epidemiology of cardiovascular disease in young individuals. Nature Reviews Cardiology, 15(4), 230–240.
  3. • Chen, S., Markman, J. L., Shimada, K., Crother, T. R., Lane, M., Abolhesn, A., Shah, P. K., & Arditi, M. (2020). Sex-Specific Effects of the Nlrp3 Inflammasome on Atherogenesis in LDL Receptor-Deficient Mice. JACC: Basic to Translational Science, 5(6), 582–598.
  4. • Davis, B. K., Wen, H., & Ting, J. P. Y. (2011). The Inflammasome NLRs in immunity, inflammation, and associated diseases. Annual Review of Immunology, 29, 707–735.
  5. • De Biase, D., Piegari, G., Prisco, F., Cimmino, I., Pirozzi, C., Mattace Raso, G., Oriente, F., Grieco, E., Papparella, S., & Paciello, O. (2020). Autophagy and NLRP3 inflammasome crosstalk in neuroinflammation in aged bovine brains. Journal of Cellular Physiology, 235(6), 5394–5403.
  6. • Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nũez, G., Schnurr, M., Espevik, T., Lien, E., Fitzgerald, K. A., Rock, K. L., Moore, K. J., Wright, S. D., Hornung, V., & Latz, E. (2010). NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature, 464(7293), 1357–1361.
  7. • Gao, Z., Chen, Z., Sun, A., & Deng, X. (2019). Gender differences in cardiovascular disease. Medicine in Novel Technology and Devices, 4, 100025.
  8. • Hawraa,H., Sawsan,M., & Saif,J., (2021).Human herpes virus 6 infection in cardiovascular diseases patients in Al-Najaf Governorate Iraq: A cross sectional study.Master’s degree. Department of medical Microbiology, Faculty of Medicine, Kerbala University.
  9. • He, J., Yang, Y., & Peng, D.-Q. (2012). Monosodium urate (MSU) crystals increase gout associated coronary heart disease (CHD) risk through the activation of NLRP3 inflammasome. International Journal of Cardiology, 1(160), 72–73.
  10. • Karunathilake, S. P., & Ganegoda, G. U. (2018). Secondary Prevention of Cardiovascular Diseases and Application of Technology for Early Diagnosis. BioMed Research International, 2018.
  11. • Kawaguchi, M., Takahashi, M., Hata, T., Kashima, Y., Usui, F., Morimoto, H., Izawa, A., Takahashi, Y., Masumoto, J., & Koyama, J. (2011). Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation, 123(6), 594–604.
  12. • Kelley, N., Jeltema, D., Duan, Y., & He, Y. (2019). The NLRP3 inflammasome: An overview of mechanisms of activation and regulation. International Journal of Molecular Sciences, 20(13), 1–24.
  13. • Liu, D., Zeng, X., Li, X., Mehta, J. L., & Wang, X. (2018). Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases. Basic Research in Cardiology, 113(1).
  14. • Marín-Aguilar, F., Lechuga-Vieco, A. V., Alcocer-Gómez, E., Castejón-Vega, B., Lucas, J., Garrido, C., Peralta-Garcia, A., Pérez-Pulido, A. J., Varela-López, A., Quiles, J. L., Ryffel, B., Flores, I., Bullón, P., Ruiz-Cabello, J., & Cordero, M. D. (2020). NLRP3 inflammasome suppression improves longevity and prevents cardiac aging in male mice. Aging Cell, 19(1), 1–14.
  15. • Saadatmand, S., Vos, J. R., Hooning, M. J., Oosterwijk, J. C., Koppert, L. B., Bock, G. H. De, Ausems, M. G., Asperen, C. J. Van, Aalfs, C. M., Gómez, E. B., Wanna, A. G. B., Noble, J. H., Carlson, M. L., Gifford, H., Dietrich, M. S., Haynes, D. S., Dawant, B. M., Saadatmand, S., Vos, J. R., … Chester, J. D. (2014). This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please c. The Laryngoscope, 2, 2–31.
  16. • Toldo, S., Marchetti, C., Mauro, A. G., Chojnacki, J., Mezzaroma, E., Carbone, S., Zhang, S., Van Tassell, B., Salloum, F. N., & Abbate, A. (2016). Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemia–reperfusion in the mouse. International Journal of Cardiology, 209, 215–220.
  17. • Tong, Y., Wang, Z., Cai, L., Lin, L., Liu, J., & Cheng, J. (2020). NLRP3 Inflammasome and Its Central Role in the Cardiovascular Diseases. Oxidative Medicine and Cellular Longevity, 2020. https://doi.org/10.1155/2020/4293206
  18. • Virani, S. S., Alonso, A., Aparicio, H. J., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Cheng, S., & Delling, F. N. (2021). Heart disease and stroke statistics—2021 update: a report from the American Heart Association. Circulation, 143(8), e254–e743.
  19. • Yazdanyar, A., & Newman, A. B. (2009). The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. Clinics in Geriatric Medicine, 25(4), 563–577.
  20. • Zheng, M., Lu, D., Li, L., Li, Q., Bian, L., Yang, H., ... & Guo, J. (2020). Research Perspectives of NLRP3 in the Pathogenesis of Cardiovascular Diseases.
  21. • Zhou, W., Chen, C., Chen, Z., Liu, L., Jiang, J., Wu, Z., Zhao, M., & Chen, Y. (2018). NLRP3: A novel mediator in cardiovascular disease. Journal of Immunology Research, 2018.
  22. • Халафли, Х. Н., Bonaventura, A., Montecucco, F., Thomas, H., Diamond, J., Vieco, A., Chaudhuri, S., Shinnar, E., Cromer, S., Perel, P., Mensah, G. A., Narula, J., Johnson, C. O., Roth, G. A., Moran, A. E., Blank, N., Lorenz, H., Song, H., Fang, F., … Koneru, A. (2018). Management of psychiatric disorders in patients with cardiovascular diseases. Basic Research in Cardiology, 23(3), 2145–2154.